ETH42
Primary Ciliary Dyskinesia (DNAI1 deficiency)
Pre-clinicalActive
Key Facts
About Ethris
Ethris is a clinical-stage biotech specializing in mRNA therapeutics for respiratory diseases, utilizing its proprietary SNIM® RNA and LNP delivery platform. The company's lead programs target rare genetic disorders like cystic fibrosis and primary ciliary dyskinesia, with a broader pipeline exploring applications in viral defense and chronic lung diseases. As a private company, Ethris has secured significant partnerships with major pharmaceutical players like AstraZeneca and Vertex Pharmaceuticals, positioning it as a key innovator in localized mRNA delivery beyond systemic vaccines.
View full company profile